LncRNA WT1-AS/miR-494-3p Regulates Cell Proliferation, Apoptosis, Migration and Invasion via PTEN/PI3K/AKT Signaling Pathway in Non-Small Cell Lung Cancer

References

• Yang C, Jia X, Zhou J, Sun Q, Ma Z. The MiR-17-92 gene cluster is a blood-based marker for cancer detection in non-small-cell lung cancer. Am J Med Sci. 2020;360(3):248–260. doi:10.1016/j.amjms.2020.05.004
   PubMed Web of Science ®Google Scholar
• Geng J, Li X, Zhou Z, Wu CL, Dai M, Bai X. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett. 2015;359(2):275–287. doi:10.1016/j.canlet.2015.01.031
   PubMed Web of Science ®Google Scholar
• Jeong JH, Choi PJ, Yi JH, Jeong SS, Lee KN. Lymph node metastasis after spontaneous regression of non-small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2019;52(2):119–123. doi:10.5090/kjtcs.2019.52.2.119
   PubMedGoogle Scholar
• Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 2020;206:107438. doi:10.1016/j.pharmthera.2019.107438
   PubMed Web of Science ®Google Scholar
• Jafari M, Ghadami E, Dadkhah T, Akhavan-Niaki H. PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234(3):2373–2385. doi:10.1002/jcp.27262
   PubMed Web of Science ®Google Scholar
• Liu HY, Chang J, Li GD, Zhang ZH, Tian J, Mu YS. MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2020;24(11):6139–6149. doi:10.26355/eurrev_202006_21509
   PubMed Web of Science ®Google Scholar
• Umar S, Soni R, Durgapal SD, Soman S, Balakrishnan S. A synthetic coumarin derivative (4-flourophenylacetamide-acetyl coumarin) impedes cell cycle at G0/G1 stage, induces apoptosis, and inhibits metastasis via ROS-mediated p53 and AKT signaling pathways in A549 cells. J Biochem Mol Toxicol. 2020;34(10):e22553. doi:10.1002/jbt.22553
   PubMed Web of Science ®Google Scholar
• Yang F, Yan Y, Yang Y, et al. MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway. Cell Signal. 2020;73:109675. doi:10.1016/j.cellsig.2020.109675
   PubMed Web of Science ®Google Scholar
• Petrek H, Yu AM. MicroRNAs in non-small cell lung cancer: gene regulation, impact on cancer cellular processes, and therapeutic potential. Pharmacol Res Perspect. 2019;7(6):e00528. doi:10.1002/prp2.528
   PubMed Web of Science ®Google Scholar
• Faversani A, Amatori S, Augello C, et al. miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget. 2017;8(5):7231–7247. doi:10.18632/oncotarget.13933
   PubMed Web of Science ®Google Scholar
• Li J, Jin B, Wang T, et al. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Cancer Biomark. 2019;26(4):501–512. doi:10.3233/CBM-181970
   PubMed Web of Science ®Google Scholar
• Li XT, Wang HZ, Wu ZW, et al. miR-494-3p regulates cellular proliferation, invasion, migration, and apoptosis by PTEN/AKT signaling in human glioblastoma cells. Cell Mol Neurobiol. 2015;35(5):679–687. doi:10.1007/s10571-015-0163-0
   PubMed Web of Science ®Google Scholar
• He H, Liao X, Yang Q, et al. MicroRNA-494-3p promotes cell growth, migration, and invasion of nasopharyngeal carcinoma by targeting Sox7. Technol Cancer Res Treat. 2018;17:1533033818809993. doi:10.1177/1533033818809993
   Web of Science ®Google Scholar
• Lin H, Huang ZP, Liu J, et al. MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. Sci Rep. 2018;8(1):10461. doi:10.1038/s41598-018-28519-2
   PubMedGoogle Scholar
• Hombach S, Kretz M. Non-coding RNAs: classification, biology and functioning. Adv Exp Med Biol. 2016;937:3–17.
   PubMed Web of Science ®Google Scholar
• Zhang XZ, Liu H, Chen SR. Mechanisms of long non-coding RNAs in cancers and their dynamic regulations. Cancers (Basel). 2020;12(5):1245. doi:10.3390/cancers12051245
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Fang L. LncRNA WT1-AS over-expression inhibits non-small cell lung cancer cell stemness by down-regulating TGF-β1. BMC Pulm Med. 2020;20(1):113. doi:10.1186/s12890-020-1146-6
   PubMed Web of Science ®Google Scholar
• Sui Y, Chi W, Feng L, Jiang J. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25. BMC Pulm Med. 2020;20(1):59. doi:10.1186/s12890-020-1064-7
   PubMed Web of Science ®Google Scholar
• Storti CB, de Oliveira RA, de Carvalho M, et al. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC). Exp Mol Pathol. 2020;112:104354. doi:10.1016/j.yexmp.2019.104354
   PubMed Web of Science ®Google Scholar
• Luo H, Zhang J, He Z, Wu S. Long noncoding RNA WT1-AS inhibits the progression of cervical cancer by sponging miR-205. Cancer Biother Radiopharm. 2020. doi:10.1089/cbr.2019.3279
   Web of Science ®Google Scholar
• Le F, Luo P, Ouyang Q, Zhong X. LncRNA WT1-AS downregulates survivin by upregulating miR-203 in papillary thyroid carcinoma. Cancer Manag Res. 2020;12:443–449. doi:10.2147/CMAR.S232294
   PubMed Web of Science ®Google Scholar
• Shin N, Stubbs M, Koblish H, et al. Parsaclisib is a next-generation phosphoinositide 3-kinase δ inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy. J Pharmacol Exp Ther. 2020;374(1):211–222. doi:10.1124/jpet.120.265538
   PubMed Web of Science ®Google Scholar
• Guo JH, Fang HY, Yang JM, et al. MicroRNA −92b acts as an oncogene by targeting PTEN/AKT in NSCLC. Cell Biochem Funct. 2020;38(8):1100–1110. doi:10.1002/cbf.3568
   PubMed Web of Science ®Google Scholar
• Qiu G, Tong W, Jiang C, et al. Long noncoding RNA WT1-AS inhibit cell malignancy via miR-494-3p in glioma. Technol Cancer Res Treat. 2020;19:1533033820919759. doi:10.1177/1533033820919759
   Web of Science ®Google Scholar
• Zhu L, Wang X, Wang T, Zhu W, Zhou X. miR‑494‑3p promotes the progression of endometrial cancer by regulating the PTEN/PI3K/AKT pathway. Mol Med Rep. 2019;19(1):581–588. doi:10.3892/mmr.2018.9649
   PubMed Web of Science ®Google Scholar